As real-world data (RWD) and real-world evidence (RWE) continue to share the limelight in pharmacoepidemiologic and pharmacoeconomic journals and congresses, the demand for defining RWD and RWE as well as a framework for leveraging real-world research has never been greater.
One of the most pressing concerns involves what constitutes “regulatory grade” real-world data and real-world evidence, and when sponsors need to ensure that research conducted using data other than those generated via clinical trials meets the definition of regulatory grade.
Create a display name to comment
This name will appear with your comment
